Back to top

Image: Bigstock

Intrexon Corporation

Read MoreHide Full Article

Intrexon’s expanding portfolio of technologies has enabled the company to develop a robust pipeline of candidates targeting a broad range of diseases including cancer and others. We are positive on Intrexon’s efforts to expand through acquisitions, exclusive channel collaborations (ECCs) and joint ventures. The company also announced the formation of a wholly-owned subsidiary-Precigen, part of its structural alternatives so that it can take better decisions of its health business. However, Intrexon depends largely on ECCs and license and collaboration deals for revenues. Any unfavorable outcome from any of the development programs could be a major setback for Intrexon and hurt its prospects. Also, shares of the company have underperformed the Medical Services industry in the past one year. Loss Estimates are stable lately ahead of the Q1 earnings results. Intrexon has a negative record of earnings surprises in recent quarters.

Published in